Health problems worth solving

Most of what is broken in health is not medicine. It is coordination, paperwork and access.

LinkedIn Email

Framed 26 Sep

HealthProblem 0027

Before a hospital or clinic can use an AI tool, the tool is tested and approved. That happens once. Afterwards, the rules mostly wait for someone to report that something went wrong. But an AI tool does not stay the way it was tested. It gets updated. It behaves differently with real patients than it did in the test. And it can work well in one place and less well in another. So a single test, done once before the tool went into use, cannot tell you whether it is still safe where you are treated today. What is missing is a way to keep testing it while it is in use, to update it carefully, and to help hospitals and clinics see for themselves how it is doing.

Who lives with itHealthcare provider governance teams · Healthcare professionals using AI · Patients receiving AI-supported care

Why nowThe Medicines and Healthcare products Regulatory Agency’s report, published on 10 September 2026, warns that reliance on one-off pre-market assessment is insufficient and calls for more continuous monitoring after deployment.

Why it mattersExisting assessment approaches suit relatively static products, while continuing safety depends on both the product and its clinical setting. A small team could begin with measuring changes in performance for a single clinical use across deployments, working with a provider to connect those measurements to review and escalation responsibilities.

Inspired by reporting from Medicines and Healthcare products Regulatory Agency

A funded startup to make a dent in High (Ainna's editorial grade)2 sources

LinkedIn Email

Solve it →Full problem

Framed 21 Sep

HealthProblem 0019

Caring for an ageing parent means medications, appointments, home visits, bills and forms, shared between siblings in different cities and often different countries. It runs on a group chat, a shared folder and whoever remembers. Things fall through, one person quietly carries most of it, and the professionals involved each see a fragment of a picture nobody holds whole.

Who lives with itAdult children caring for parents · home-care workers · family doctors seeing only their slice

Why nowPopulations are ageing across high-income countries and many middle-income ones while the paid care workforce is not growing with them, so more of this coordination falls to families who were never set up to do it.

Why it mattersThis is coordination, exactly what software is good at, and the tools built for it have yet to become the way families actually run it. The work is already being done; it is simply being done badly, by people with no tools and no training, at one of the hardest times of their lives.

Framed by Ainna editorial

A funded startup to make a dent in Critical (Ainna's editorial grade)

LinkedIn Email

Solve it →Full problem

Framed 21 Sep

HealthProblem 0005

When a patient has an infection, the doctor, nurse or pharmacist has to choose an antibiotic that will work, and which ones still work depends on the place: resistance differs between countries and regions, and it is growing. The surest way to know is a laboratory test, but much prescribing happens in clinics without a laboratory nearby, and a test takes days. So the decision is based on guidance and national advice that may not match local patterns. What happens next is rarely recorded, so a failed treatment does not inform the next prescriber, and the maps of resistance that guide treatment are drawn from the minority of cases that reach a laboratory, often missing the places where resistance is worst.

Who lives with itPatients with common infections · doctors, nurses and pharmacists prescribing without a laboratory · hospitals and health ministries setting treatment guidelines

Why nowThe World Health Organization reported on 13 October 2025 that one in six laboratory-confirmed common bacterial infections worldwide were resistant to antibiotics in 2023, rising to one in three in South-East Asia and the Eastern Mediterranean, and that resistance rose in over 40% of the combinations it monitors between 2018 and 2023. Yet 48% of countries reported no data that year, and about half of those that did lacked systems to produce reliable data.

Why it mattersLaboratories are costly and slow to build, and rapid tests answer for one patient at a time without building a shared picture. The knowledge that matters, which drug failed for which infection and where, is lost at the point of care. Health ministries and funders tracking resistance, hospital groups writing local guidelines, and makers of tests and prescribing software would pay for a way to see what still works, place by place.

Inspired by reporting from World Health Organization

A funded startup to make a dent in Critical (Ainna's editorial grade)2 sources

LinkedIn Email

Solve it →Full problem

The same Radar runs in your context. What you see here is Problem Radar, free. Tune it to your market and it listens to the sectors, themes and geographies you set, landing every find in your portfolio, graded: that's the Team plan (coming soon). Tune it to your company and it listens to your innovation agenda and to your own people: that's Enterprise. Both are private to you: nothing they find is ever published.

Prefer a feed reader? RSS · JSON Feed

3 problems. Pick one.Grade your idea

Health problems worth solving

Stale AI approvals: Medical AI keeps changing; its safety checks haven't kept up

Uncoordinated family care: Families coordinate elder care in a group chat

Doctors uncertain which antibiotics still work where they practise: Resistance data rarely reaches the clinics where antibiotics are prescribed